New pill aims to stop chronic hives fast when antihistamines fail
NCT ID NCT07665996
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This early-phase trial tests a new drug called TLL-018 in 36 adults with moderate-to-severe chronic spontaneous urticaria (hives) that standard antihistamines can't control. The goal is to see how quickly TLL-018 reduces itching and hives after the first dose. Participants will receive either 10 mg, 20 mg, or a placebo twice daily for a short period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TLL-018
- What this could lead to
- If it works, this could point toward a faster-acting treatment option for people with chronic hives that don't respond to standard antihistamines.
- What could go wrong
- This is a very early, small trial (36 people) testing rapid onset only. The drug may not work or could have side effects. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA (CSU) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second People's Hospital of Chengdu
Chengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.